Investment
Features
FeesSafety
Academy
More
Pluang+

Two New Jersey residents lose $54,000 in cash and Bitcoin scams involving bank impersonation.

Market News
28 Sep 2026
The Daily Hodl
View Source
Bearish
Two New Jersey residents lose $54,000 in cash and Bitcoin scams involving bank impersonation.

Two residents of New Jersey were scammed out of a total of $54,000 through two separate schemes. One victim was tricked into transferring $29,500 into a Bitcoin account after a scammer took control of her computer, while another was convinced to hand over $24,500 in cash to a supposed transportation service after receiving a fake bank alert about fraudulent transactions. Police warn residents to verify urgent money warnings directly with their banks and never to buy cryptocurrency or hand cash to strangers based on unsolicited calls or texts. These incidents highlight ongoing risks of financial scams involving cryptocurrency and bank impersonation.

New Jersey residents losing $24,500 in cash and $29,500 in a Bitcoin scam is the subject, with Pluang market data as of Sep 28, 2026 23:32 WIB providing context. For readers following cryptocurrency trends, here is Pluang's market snapshot: out of 50 major cryptocurrencies priced today, 11 rose and 38 fell. Notable movers include FIL (Filecoin) down 7.61% at Rp19.003, LINK (Chainlink) up 7.05% at Rp270.751, and UNI (Uniswap) down 6.84% at Rp161.491. The most notable figure is LINK's 7.05% increase.

More News

Vertex Pharmaceuticals rises on strong cystic fibrosis sales and promising kidney drug trials, UBS hikes price target.

Vertex Pharmaceuticals rises on strong cystic fibrosis sales and promising kidney drug trials, UBS hikes price target.

Vertex Pharmaceuticals reported a 12% revenue increase to $3.33 billion in Q2, driven by its dominant cystic fibrosis treatments. UBS raised its price target from $585 to $615, reflecting confidence in Vertex's strong financials and growth potential....

Analyst Insights
Bullish
2 hours ago
Accenture's stock jumps 37.6% on booming AI demand and strong financials ahead of Q4 earnings.

Accenture's stock jumps 37.6% on booming AI demand and strong financials ahead of Q4 earnings.

Accenture's stock surged 37.6% recently, driven by rising demand for AI services and new AI-focused offerings. The company outpaced industry growth and secured 100 new clients for advanced AI projects in one quarter. An analyst raised the price targe...

Analyst Insights
Bullish
3 hours ago
SpaceX nears Starship's first orbital launch and Starlink V3 deployment, boosting investor optimism.

SpaceX nears Starship's first orbital launch and Starlink V3 deployment, boosting investor optimism.

SpaceX, trading near $148 per share with a market cap of about $1.95 trillion, is preparing for Starship's first orbital mission and the deployment of its first operational Starlink V3 satellites. This milestone is key for expanding Starlink's global...

Market News
Bullish
3 hours ago
10x Genomics gets Buy rating despite insider selling and valuation concerns.

10x Genomics gets Buy rating despite insider selling and valuation concerns.

Argus Research initiated coverage on 10x Genomics with a Buy rating and a $110 price target, suggesting a 28% upside from its current price of around $85. The stock shows strong momentum, trading well above its 50-day and 200-day moving averages. How...

Analyst Insights
Neutral
3 hours ago
Morgan Stanley upgrades Cullen/Frost Bankers with strong institutional buying and a $201 price target.

Morgan Stanley upgrades Cullen/Frost Bankers with strong institutional buying and a $201 price target.

Morgan Stanley reaffirmed an "Overweight" rating on Cullen/Frost Bankers, Inc., raising its price target to $201, signaling confidence in the bank's prospects. Major institutional investors like State Street Corp and BlackRock have increased or initi...

Analyst Insights
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App